CaaX-Protein Prenyltransferase Inhibitors

Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications

Volumn , Issue , 2009, Pages 813-857

  Schlitzer, Martin ^a   Ortmann, Regina ^a   Altenkämper, Mirko ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

CaaX tetrapeptides, CVIM alternative substrates inhibiting peptide farnesylation; CaaX protein prenyltransferase inhibitors; Piperidin based farnesyltransferase inhibitors

Indexed keywords

EID: 84855496732     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470508169.ch34     Document Type: Chapter

References (105)

1. Appels, N. M.; Beijnen, J. H.; Schellens, J. H. Development of farnesyl transferase inhibitors: a review. Oncologist 2005, 10, 565-578.
2. Margaritora, S.; Cesario, A.; Porziella, V.; Granone, P.; Catassi, A.; Russo, P. Farnesyltransferase Inhibitors: overviewof their action and role in solid malignancy therapy. Lett. Drug Des. Discov. 2005, 2, 26-35.
3. Basso, A. D.; Kirschmeier, P.; Bishop, W. R. Lipid posttranslational modifications. Farnesyl transferase inhibitors. J. Lipid Res. 2006, 47, 15-31.
4. Konstantinopoulos, P. A.; Karamouzis, M. V.; Papavassiliou, A. G. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat. Rev. Drug Discov. 2007, 6, 541-555.
5. Sousa, S. F.; Fernandes, P. A.; Ramos, M. J. Farnesyltransferase-new insights into the zinc-coordination sphere paradigm: evidence for a carboxylate-shift mechanism. Biophys. J. 2005, 88, 483-494.
6. Sousa, S. F.; Fernandes, P. A.; Ramos, M. J. Theoretical studies on farnesyltransferase: the distances paradox explained. Proteins 2007, 66, 205-218.
7. Lane, K. T.; Beese, L. S. Thematic review series: lipid posttranslational modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I. J. Lipid Res. 2006, 47, 681-699.
8. Reid, T. S.; Terry, K. L.; Casey, P. J.; Beese, L. S. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J Mol Biol 2004, 343, 417-433.
9. Long, S. B.; Casey, P. J.; Beese, L. S. Reaction path of protein farnesyltransferase at atomic resolution. Nature 2002, 419, 645-650.
10. Qian, Y.; Sebti, S. M.; Hamilton, A. D. Farnesyltransferase as a target for anticancer drug design. Biopolymers 1997, 43, 25-41.
11. Leonard, D. M. Ras farnesyltransferase: a newtherapeutic target. J. Med. Chem. 1997, 40, 2971-2990.
12. Ayral-Kaloustian, S.; Salaski, E. J. Protein farnesyltransferase inhibitors. Curr. Med. Chem. 2002, 9, 1003-1032.
13. Graham, S. L. Review Oncologic, Endocrine & Metabolic: Inhibitors of protein farnesylation: a new approach to cancer chemotherapy. Expert Opin. Ther. Pat. 1995, 5, 1269-1285.
14. Ohkanda, J.; Blaskovich, M. A.; Sebti, S. M.; Hamilton, A. D. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents. Prog. Cell Cycle Res. 2003, 5, 211-217.
15. Ohkanda, J.; Knowles, D. B.; Blaskovich, M. A.; Sebti, S. M.; Hamilton, A. D. Inhibitors of protein farnesyltransferase as novel anticancer agents. Curr. Top. Med. Chem. 2002, 2, 303-323.
16. Huang, C.; Rokosz, L.; Farnesyltransferase inhibitors: recent advances. Expert Opin. Ther. Pat. 2004, 14, 175-186.
17. Bell, I. M. Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy? J. Med. Chem. 2004, 47, 1869-1878.
18. Puntambekar,D. S.; Giridhar, R.;Yadav, M. R. Inhibition of farnesyltransferase: a rational approach to treat cancer? J. Enzyme Inhib. Med. Chem. 2007, 22, 127-140.
19. Gibbs, R. A.; Zahn, T. J.; Sebolt-Leopold, J. S. Non-peptidic prenyltransferase inhibitors: diverse structural classes and surprising anti-cancer mechanisms. Curr. Med. Chem. 2001, 8, 1437-1465.
20. End, D. W. Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway. Invest. New Drugs 1999, 17, 241-258.
21. Halazy, S.; Gotteland, J. -P.; Lamothe, M.; Perrin, D.; Hill, B. T. Rationally designed FPTase inhibitors. Drugs Future 1997, 22,1133-1146.
22. Sebti, S. M.; Adjei, A. A. Farnesyltransferase inhibitors. Semin. Oncol. 2004, 31, 28-39.
23. Sebti, S. M.; Hamilton, A. D. New approaches to anticancer drug design based on the inhibition of farnesyltransferase. Drug Discov. Today 1998, 3, 26-33.
24. Lee, H. Y.; Sohn, J. H.; Kwon, B. M. Development of tripeptidyl farnesyltransferase inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 1599-1602.
25. Houssin, R.; Pommery, J.; Salaun, M. C.; Deweer, S.; Goossens, J. F.; Chavatte, P.; Henichart, J. P. Design, synthesis, and pharmacological evaluation of newfarnesyl protein transferase inhibitors. J. Med. Chem. 2002, 45, 533-536.
26. Appels, N. M.; Bolijn, M. J.; Chan, K.; Stephens, T. C.; Hoctin-Boes, G.; Middleton, M.; Beijnen, J. H.; de Bono, J. S.; Harris, A. L.; Schellens, J. H. Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer. Br. J. Cancer 2008, 98, 1951-1958.
27. Sakowski, J.; Bohm, M.; Sattler, I.; Dahse, H. M.; Schlitzer, M. Synthesis, molecular modeling, and structure-activity relationship of benzophenone-based CAAX-peptidomimetic farnesyltransferase inhibitors. J. Med. Chem. 2001, 44, 2886-2899.
28. Reid, T. S.; Long, S. B.; Beese, L. S. Crystallographic analysis reveals that anticancer clinical candidate L-778,123 inhibits protein farnesyltransferase and geranylgeranyltransferase-I by different binding modes. Biochemistry 2004, 43, 9000-9008.
29. Millet, R.; Domarkas, J.; Houssin, R.; Gilleron, P.; Goossens, J. F.; Chavatte, P.; Loge, C.; Pommery, N.; Pommery, J.; Henichart, J. P. Potent and selective farnesyl transferase inhibitors. J. Med. Chem. 2004, 47, 6812-6820.
30. Ryckebusch, A.; Gilleron, P.; Millet, R.; Houssin, R.; Lemoine, A.; Pommery, N.; Grellier, P.; Sergheraert, C.; Henichart, J. P. Novel N-(4-piperidinyl)benzamide antimalarials with mammalian protein farnesyltransferase inhibitory activity. Chem. Pharm. Bull. (Tokyo) 2005, 53, 1324-1326.
31. Gilleron, P.; Millet, R.; Houssin, R.; Wlodarczyk, N.; Farce, A.; Lemoine, A.; Goossens, J. F.; Chavatte, P.; Pommery, N.; Henichart, J. P. Solid-phase synthesis and pharmacological evaluation of a library of peptidomimetics as potential farnesyltransferase inhibitors: an approach to new lead compounds. Eur. J. Med. Chem. 2006, 41, 745-755.
32. Gilleron, P.; Wlodarczyk, N.; Houssin, R.; Farce, A.; Laconde, G.; Goossens, J. F.; Lemoine, A.; Pommery, N.; Henichart, J. P.; Millet, R. Design, synthesis and biological evaluation of substituted dioxodibenzothiazepines and dibenzocycloheptanes as farnesyltransferase inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 5465-5471.
33. Dinsmore, C. J.; Bell, I. M. Inhibitors of farnesyltransferase and geranylgeranyltransferase-I for antitumor therapy: substrate-based design, conformational constraint and biological activity. Curr. Top. Med. Chem. 2003, 3, 1075-1093.
34. El Oualid, F.; Cohen, L. H.; van der Marel, G. A.; Overhand, M. Inhibitors of protein: geranylgeranyl transferases. Curr. Med. Chem. 2006, 13, 2385-2427.
35. Ding, C. Z.; Batorsky, R.; Bhide, R.; Chao, H. J.; Cho, Y.; Chong, S.; Gullo-Brown, J.; Guo, P.; Kim, S. H.; Lee, F.; Leftheris, K.; Miller, A.; Mitt, T.; Patel, M.; Penhallow, B. A.; Ricca, C.; Rose, W. C.; Schmidt, R.; Slusarchyk, W. A.; Vite, G.; Yan, N.; Manne, V.; Hunt, J. T. Discovery and structure-activity relationships of imidazole-containing tetrahydrobenzodiazepine inhibitors of farnesyltransferase. J. Med. Chem. 1999, 42, 5241-5253.
36. Hunt, J.T.;Ding, C. Z.; Batorsky, R.;Bednarz, M.; Bhide,R.; Cho,Y.;Chong, S.;Chao, S.; Gullo-Brown, J.; Guo, P.; Kim, S. H.;Lee,F.Y.; Leftheris, K.;Miller, A.;Mitt,T.; Patel, M.; Penhallow, B. A.; Ricca, C.; Rose,W. C.; Schmidt, R.; Slusarchyk,W. A.;Vite, G.; Manne, V. Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. J. Med. Chem. 2000, 43, 3587-3595.
37. Reid, T. S.; Beese, L. S. Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity. Biochemistry 2004, 43, 6877-6884.
38. Ohkanda, J.; Strickland, C. L.; Blaskovich, M. A.; Carrico, D.; Lockman, J.W.; Vogt, A.; Bucher, C. J.; Sun, J.; Qian,Y.; Knowles, D.; Pusateri, E. E.; Sebti, S. M.; Hamilton, A. D. Structure-based design of imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase. Org. Biomol. Chem. 2006, 4, 482-492.
39. Vasudevan, A.; Qian, Y.; Vogt, A.; Blaskovich, M. A.; Ohkanda, J.; Sebti, S. M.; Hamilton, A. D. Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I. J. Med. Chem. 1999, 42, 1333-1340.
40. Ganguly,A. K.; Doll, R. J.; Girijavallabhan,V. M. Farnesyl protein transferase inhibition: a novel approach to anti-tumor therap. The discovery and development of SCH 66336. Curr. Med. Chem. 2001, 8, 1419-1436.
41. Taveras, A. G.; Kirschmeier, P.; Baum, C. M. Sch-66336 (Sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations. Curr. Top. Med. Chem. 2003, 3, 1103-1114.
42. Strickland, C. L.; Weber, P. C.; Windsor, W. T.; Wu, Z.; Le, H. V.; Albanese, M. M.; Alvarez, C. S.; Cesarz, D.; del Rosario, J.; Deskus, J.; Mallams, A. K.; Njoroge, F. G.; Piwinski, J. J.; Remiszewski, S.; Rossman, R. R.; Taveras, A. G.; Vibulbhan, B.; Doll, R. J.; Girijavallabhan,V. M.; Ganguly,A.K. Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships. J. Med. Chem. 1999, 42, 2125-2135.
43. Venet, M.; End, D.; Angibaud, P. Farnesyl protein transferase inhibitor ZARNESTRA R115777-history of a discovery. Curr. Top. Med. Chem. 2003, 3, 1095-1102.
44. Tong, Y.; Lin, N. H.; Wang, L.; Hasvold, L.; Wang, W.; Leonard, N.; Li, T.; Li, Q.; Cohen, J.; Gu, W. Z.; Zhang, H.; Stoll, V.; Bauch, J.; Marsh, K.; Rosenberg, S. H.; Sham, H. L. Discovery of potent imidazole and cyanophenyl containing farnesyltransferase inhibitors with improved oral bioavailability. Bioorg. Med. Chem. Lett. 2003, 13, 1571-1574.
45. Lin, N. H.;Wang, L.; Cohen, J.; Gu,W. Z.; Frost, D.; Zhang, H.; Rosenberg, S.; Sham, H. Synthesis and biological evaluation of 4-[3-biphenyl-2-yl-1-hydroxy-1-(3-methyl-3Himidazol-4-yl)-prop-2-ynyl]-1-yl-benzonitrile as novel farnesyltransferase inhibitor. Bioorg. Med. Chem. Lett. 2003, 13, 1293-1296.
46. Lin, N. H.;Wang, L.;Wang, X.;Wang, G. T.; Cohen, J.; Gu,W. Z.; Zhang, H.; Rosenberg, S. H.; Sham, H. L. Synthesis and biological evaluation of 1-benzyl-5-(3-biphenyl-2-ylpropyl)-1H-imidazole as novel farnesyltransferase inhibitor. Bioorg. Med. Chem. Lett. 2004, 14, 5057-5062.
47. Bohm, M.; Mitsch, A.; Wissner, P.; Sattler, I.; Schlitzer, M. Exploration of novel aryl binding sites of farnesyltransferase using molecular modeling and benzophenone-based farnesyltransferase inhibitors. J. Med. Chem. 2001, 44, 3117-3124.
48. Schlitzer, M. Structure based design of benzophenone-based non-thiol farnesyltransferase inhibitors. Curr. Pharm. Des. 2002, 8, 1713-22.
49. Mitsch, A.; Wissner, P.; Silber, K.; Haebel, P.; Sattler, I.; Klebe, G.; Schlitzer, M. Nonthiol farnesyltransferase inhibitors: N-(4-tolylacetylamino-3-benzoylphenyl)-3-arylfurylacrylic acid amides. Bioorg. Med. Chem. 2004, 12, 4585-4600.
50. Dinsmore, C. J.; Williams, T. M.; O'Neill, T. J.; Liu, D.; Rands, E.; Culberson, J. C.; Lobell, R. B.;Koblan, K. S.;Kohl, N. E.; Gibbs, J. B.; Oliff, A. I.; Graham, S. L.; Hartman, G. D. Imidazole-containing diarylether and diarylsulfone inhibitors of farnesyl-protein transferase. Bioorg. Med. Chem. Lett. 1999, 9, 3301-3306.
51. Perez, M.; Maraval, C.; Dumond, S.; Lamothe, M.; Schambel, P.; Etievant, C.; Hill, B. Synthesis and evaluation of a novel series of farnesyl protein transferase inhibitors as non-peptidic CAAX tetrapeptide analogues. Bioorg. Med. Chem. Lett. 2003, 13, 1455-1458.
52. Lee, J.; Kim, J.; Koh, J. S.; Chung, H. H.; Kim, K. H. Hydantoin derivatives as nonpeptidic inhibitors of Ras farnesyl transferase. Bioorg. Med. Chem. Lett. 2006, 16, 1954-1956.
53. Le Diguarher, T.; Ortuno, J. C.; Dorey, G.; Shanks, D.; Guilbaud, N.; Pierre, A.; Fauchere, J. L.; Hickman, J. A.; Tucker, G. C.; Casara, P. J. Parallel liquid synthesis of N,N0-Disubstituted 3-amino azepin-2-ones as potent and specific farnesyl transferase inhibitors. Bioorg. Med. Chem. 2003, 11, 3193-3204.
54. Le Diguarher, T.; Ortuno, J. C.; Shanks, D.; Guilbaud, N.; Pierre, A.; Raimbaud, E.; Fauchere, J. L.; Hickman, J. A.;Tucker,G. C.; Casara, P. J. Synthesis ofN,N0-disubstituted 3-aminobenzo[c] and [d]azepin-2-ones as potent and specific farnesyl transferase inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 767-771.
55. Saha, A. K.; Liu, L.; Simoneaux, R.; DeCorte, B.; Meyer, C.; Skrzat, S.; Breslin, H. J.; Kukla, M. J.; End, D. W. Novel triazole based inhibitors of Ras farnesyl transferase. Bioorg. Med. Chem. Lett. 2005, 15, 5407-5411.
56. Nara, S.; Tanaka, R.; Eishima, J.; Hara, M.; Takahashi, Y.; Otaki, S.; Foglesong, R. J.; Hughes, P. F.; Turkington, S.; Kanda,Y. Discovery and structure-activity relationships of novel piperidine inhibitors of farnesyltransferase. J. Med. Chem. 2003, 46, 2467-2473.
57. Tanaka, R.; Rubio, A.; Harn, N. K.; Gernert, D.; Grese, T. A.; Eishima, J.; Hara, M.;Yoda, N.; Ohashi, R.; Kuwabara, T.; Soga, S.; Akinaga, S.; Nara, S.; Kanda, Y. Design and synthesis of piperidine farnesyltransferase inhibitors with reduced glucuronidation potential. Bioorg. Med. Chem. 2007, 15, 1363-1382.
58. Castellano, S.; Fiji, H. D.; Kinderman, S. S.;Watanabe, M.; Leon, P.; Tamanoi, F.; Kwon, O. Small-molecule inhibitors of protein geranylgeranyltransferase type I. J. Am. Chem. Soc. 2007, 129, 5843-5845.
59. Watanabe, M.; Fiji, H. D.; Guo, L.; Chan, L.; Kinderman, S. S.; Slamon, D. J.; Kwon, O.; Tamanoi, F. Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. J. Biol. Chem. 2008, 283, 9571-9579.
60. Peterson, Y. K.; Kelly, P.; Weinbaum, C. A.; Casey, P. J. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity. J. Biol. Chem. 2006, 281, 12445-12450.
61. Peng, H.; Carrico, D.; Thai, V.; Blaskovich, M.; Bucher, C.; Pusateri, E. E.; Sebti, S. M.; Hamilton, A. D. Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyltransferase-I. Org. Biomol. Chem. 2006, 4, 1768-1784.
62. Carrico, D.; Blaskovich, M. A.; Bucher, C. J.; Sebti, S. M.; Hamilton, A. D. Design, synthesis, and evaluation of potent and selective benzoyleneurea-based inhibitors of protein geranylgeranyltransferase-I. Bioorg. Med. Chem. 2005, 13, 677-688.
63. Singh, S. B.; Zink, D. L.; Doss, G. A.; Polishook, J. D.; Ruby, C.; Register, E.; Kelly, T. M.; Bonfiglio, C.; Williamson, J. M.; Kelly, R. Citrafungins A and B, two new fungal metabolite inhibitors of GGTase I with antifungal activity. Org. Lett. 2004, 6, 337-340.
64. Ferri, N.;Yokoyama, K.; Sadilek, M.; Paoletti, R.; Apitz-Castro, R.; Gelb, M. H.; Corsini, A. Ajoene, a garlic compound, inhibits protein prenylation and arterial smooth muscle cell proliferation. Br. J. Pharmacol. 2003, 138, 811-818.
65. Philips, M. R.; Cox, A. D. Geranylgeranyltransferase I as a target for anti-cancer drugs. J. Clin. Invest. 2007, 117, 1223-1225.
66. Blum, R.; Cox, A. D.; Kloog, Y. Inhibitors of chronically active Ras: potential for treatment of human malignancies. Recent Pat. Anticancer Drug Discov. 2008, 3, 31-47.
67. Caraglia, M.; Budillon, A.; Tagliaferri, P.; Marra, M.; Abbruzzese, A.; Caponigro, F. Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications. Curr. Drug Targets 2005, 6, 301-323.
68. Lujan, H. D.; Mowatt, M. R.; Chen, G. Z.; Nash, T. E. Isoprenylation of proteins in the protozoan Giardia lamblia. Mol. Biochem. Parasitol. 1995, 72, 121-127.
69. Chen, G. Z.; Bennett, J. L. Characterization of mevalonate-labeled lipids isolated from parasite proteins in Schistosoma mansoni. Mol. Biochem. Parasitol. 1993, 59, 287-292.
70. Chakrabarti, D.; Azam, T.; DelVecchio, C.; Qiu, L.; Park,Y. I.; Allen, C. M. Protein prenyl transferase activities of Plasmodium falciparum. Mol. Biochem. Parasitol. 1998, 94, 175-184.
71. Chakrabarti, D.; Da Silva, T.; Barger, J.; Paquette, S.; Patel, H.; Patterson, S.; Allen, C. M. Protein farnesyltransferase and protein prenylation in Plasmodium falciparum. J. Biol. Chem. 2002, 277, 42066-42073.
72. Yokoyama, K.; Trobridge, P.; Buckner, F. S.; Van Voorhis,W. C.; Stuart, K. D.; Gelb, M. H. Protein farnesyltransferase from Trypanosoma bruc. A heterodimer of 61- and 65-kDa subunits as a new target for antiparasite therapeutics. J. Biol. Chem. 1998, 273, 26497-26505.
73. Buckner, F. S.;Yokoyama, K.; Nguyen, L.; Grewal, A.; Erdjument-Bromage, H.; Tempst, P.; Strickland, C. L.; Xiao, L.; Van Voorhis, W. C.; Gelb, M. H. Cloning, heterologous expression, and distinct substrate specificity of protein farnesyltransferase from Trypanosoma brucei. J. Biol. Chem. 2000, 275, 21870-21876.
74. Buckner, F. S.; Eastman, R. T.; Nepomuceno-Silva, J. L.; Speelmon, E. C.; Myler, P. J.; Van Voorhis, W. C.; Yokoyama, K. Cloning, heterologous expression, and substrate specificities of protein farnesyltransferases from Trypanosoma cruzi and Leishmania major. Mol. Biochem. Parasitol. 2002, 122, 181-188.
75. Ibrahim, M.; Azzouz, N.; Gerold, P.; Schwarz, R. T. Identification and characterisation of Toxoplasma gondii protein farnesyltransferase. Int. J. Parasitol. 2001, 31, 1489-1497.
76. Kumagai, M.; Makioka, A.; Takeuchi, T.; Nozaki, T. Molecular cloning and characterization of a protein farnesyltransferase from the enteric protozoan parasite Entamoeba histolytica. J. Biol. Chem. 2004, 279, 2316-2323.
77. Yokoyama, K.; Gillespie, J. R.; Van Voorhis, W. C.; Buckner, F. S.; Gelb, M. H. Protein geranylgeranyltransferase-I of Trypanosoma cruzi. Mol. Biochem. Parasitol. 2008, 157, 32-43.
78. Makioka, A.; Kumagai, M.; Takeuchi, T.; Nozaki, T. Characterization of protein geranylgeranyltransferase I from the enteric protist Entamoeba histolytica. Mol. Biochem. Parasitol. 2006, 145, 216-225.
79. Pendyala, P. R.; Ayong, L.; Eatrides, J.; Schreiber, M.; Pham, C.; Chakrabarti, R.; Fidock, D. A.; Allen, C. M.; Chakrabarti, D. Characterization of a PRL protein tyrosine phosphatase from Plasmodium falciparum. Mol. Biochem. Parasitol. 2008, 158, 1-10.
80. Schlitzer, M. Inhibition of farnesyltransferase as a strategy for the development of novel anti-malarials. Curr. Med. Chem. Antiinfect Agents 2005, 4, 277-286.
81. Carrico, D.; Ohkanda, J.; Kendrick, H.; Yokoyama, K.; Blaskovich, M. A.; Bucher, C. J.; Buckner, F. S.;VanVoorhis,W. C.; Chakrabarti, D.; Croft, S. L.; Gelb, M. H.; Sebti, S. M.; Hamilton, A. D. In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. Bioorg. Med. Chem. 2004, 12, 6517-6526.
82. Glenn, M. P.; Chang, S. Y.; Hucke, O.; Verlinde, C. L.; Rivas, K.; Horney, C.; Yokoyama, K.; Buckner, F. S.; Pendyala, P. R.; Chakrabarti, D.; Gelb, M.; Van Voorhis,W. C.; Sebti, S. M.; Hamilton, A. D. Structurally simple farnesyltransferase inhibitors arrest the growth of malaria parasites. Angew. Chem. Int. Ed. Engl. 2005, 44, 4903-4906.
83. Wiesner, J.; Mitsch, A.; Jomaa, H.; Schlitzer,M. Structure-activity relationships of novel anti-malarial agent. Part 7: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl) acrylic acid amides with polar moieties. Bioorg. Med. Chem. Lett. 2003, 13, 2159-2161.
84. Wiesner, J.; Kettler, K.; Sakowski, J.; Ortmann, R.; Katzin, A. M.; Kimura, E. A.; Silber, K.; Klebe, G.; Jomaa, H.; Schlitzer, M. Farnesyltransferase inhibitors inhibit the growth of malaria parasites in vitro and in vivo. Angew. Chem. Int. Ed. Engl. 2004, 43, 251-254.
85. Kohring, K.; Wiesner, J.; Altenkämper, M.; Sakowski, J.; Silber, K.; Hillebrecht, A.; Haebel, P.; Dahse, H. M.; Ortmann, R.; Jomaa, H.; Klebe, G.; Schlitzer, M. Development of benzophenone-based farnesyltransferase inhibitors as novel antimalarials. ChemMedChem 2008, 3(8),1217-1231.
86. Buckner, F. S.; Eastman, R. T.; Yokoyama, K.; Gelb, M. H.; Van Voorhis, W. C. Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis. Curr. Opin. Investig. Drugs 2005, 6, 791-797.
87. Eastman, R. T.; Buckner, F. S.; Yokoyama, K.; Gelb, M. H.; Van Voorhis,W. C. Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. J. Lipid Res. 2006, 47, 233-240.
88. Nallan, L.; Bauer, K. D.; Bendale, P.; Rivas, K.; Yokoyama, K.; Horney, C. P.; Pendyala, P. R.; Floyd, D.; Lombardo, L. J.;Williams, D. K.; Hamilton, A.; Sebti, S.;Windsor,W. T.; Weber, P. C.; Buckner, F. S.; Chakrabarti, D.; Gelb, M. H.; Van Voorhis, W. C. Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J. Med. Chem. 2005, 48, 3704-3713.
89. Bendale, P.; Olepu, S.; Suryadevara, P. K.; Bulbule, V.; Rivas, K.; Nallan, L.; Smart, B.; Yokoyama, K.; Ankala, S.; Pendyala, P. R.; Floyd, D.; Lombardo, L. J.;Williams, D. K.; Buckner, F.S.; Chakrabarti, D.; Verlinde, C. L.; Van Voorhis, W. C.; Gelb, M.H. Second generation tetrahydroquinoline-based protein farnesyltransferase inhibitors as antimalarials. J. Med. Chem. 2007, 50, 4585-4605.
90. VanVoorhis,W. C.; Rivas, K. L.; Bendale, P.; Nallan, L.; Horney, C.; Barrett, L. K.; Bauer, K. D.; Smart, B. P.; Ankala, S.; Hucke, O.;Verlinde, C. L.; Chakrabarti, D.; Strickland, C.; Yokoyama, K.; Buckner, F. S.; Hamilton, A. D.;Williams, D. K.; Lombardo, L. J.; Floyd, D.; Gelb, M. H. Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob. Agents Chemother. 2007, 51, 3659-3671.
91. Bulbule, V. J.; Rivas, K.; Verlinde, C. L.; Van Voorhis, W. C.; Gelb, M. H. 2-Oxotetrahydroquinoline-based antimalarials with high potency and metabolic stability. J. Med. Chem. 2008, 51, 384-387.
92. Ohkanda, J.; Buckner, F. S.; Lockman, J.W.; Yokoyama, K.; Carrico, D.; Eastman, R.; de Luca-Fradley, K.; Davies,W.; Croft, S. L.; Van Voorhis,W. C.; Gelb, M. H.; Sebti, S. M.; Hamilton, A. D. Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents. J. Med. Chem. 2004, 47, 432-445.
93. Hucke, O.; Gelb, M. H.; Verlinde, C. L.; Buckner,F. S. The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J. Med. Chem. 2005, 48, 5415-5418.
94. Esteva, M. I.; Kettler, K.; Maidana, C.; Fichera, L.; Ruiz, A.M.; Bontempi, E. J.; Andersson, B.; Dahse, H. M.; Haebel, P.; Ortmann, R.; Klebe, G.; Schlitzer, M. Benzophenone-based farnesyltransferase inhibitors with high activity against Trypanosoma cruzi. J. Med. Chem. 2005, 48, 7186-7191.
95. Yokoyama, K.; Trobridge, P.; Buckner, F. S.; Scholten, J.; Stuart, K. D.; Van Voorhis, W. C.; Gelb, M. H. The effects of protein farnesyltransferase inhibitors on trypanosomatids: inhibition of protein farnesylation and cell growth. Mol. Biochem. Parasitol. 1998, 94, 87-97.
96. Ye, J.;Wang, C.; Sumpter, R., Jr.; Brown, M. S.; Goldstein, J. L.; Gale, M., Jr. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc. Natl. Acad. Sci. USA. 2003, 100, 15865-15870.
97. Glenn, J. S.; Marsters, J. C., Jr.; Greenberg, H. B. Use of a prenylation inhibitor as a novel antiviral agent. J. Virol. 1998, 72, 9303-9306.
98. Bordier, B. B.; Marion, P. L.; Ohashi, K.; Kay, M. A.; Greenberg, H. B.; Casey, J. L.; Glenn, J. S. A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. J. Virol. 2002, 76, 10465-10472.
99. Bordier, B. B.; Ohkanda, J.; Liu, P.; Lee, S. Y.; Salazar, F. H.; Marion, P. L.; Ohashi, K.; Meuse, L.; Kay, M. A.; Casey, J. L.; Sebti, S. M.; Hamilton, A. D.; Glenn, J. S. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J. Clin. Invest. 2003, 112, 407-414.
100. Song, J. L.; White, T. C. RAM2: an essential gene in the prenylation pathway of Candida albicans. Microbiology 2003, 149, 249-259.
101. McGeady, P.; Logan, D. A.; Wansley, D. L. A protein-farnesyl transferase inhibitor interferes with the serum-induced conversion of Candida albicans from a cellular yeast form to a filamentous form. FEMS Microbiol. Lett. 2002, 213, 41-44.
102. Vallim, M. A.; Fernandes, L.; Alspaugh, J. A. The RAM1 gene encoding a proteinfarnesyltransferase beta-subunit homologue is essential in Cryptococcus neoformans. Microbiology 2004, 150, 1925-1935.
103. Fernandes, L.; Paes, H. C.; Tavares, A. H.; Silva, S. S.; Dantas, A.; Soares, C. M.; Torres, F. A.; Felipe, M. S. Transcriptional profile of ras1 and ras2 and the potential role of farnesylation in the dimorphism of the human pathogen Paracoccidioides brasiliensis. FEMS Yeast Res. 2008, 8, 300-310.
104. Kelly, R.; Card, D.; Register, E.; Mazur, P.;Kelly,T.;Tanaka, K. I.; Onishi, J.;Williamson, J. M.; Fan, H.; Satoh, T.; Kurtz, M. Geranylgeranyltransferase I of Candida albicans: null mutants or enzyme inhibitors produce unexpected phenotypes. J. Bacteriol. 2000, 182, 704-713.
105. Murthi, K. K.; Smith, S. E.; Kluge, A. F.; Bergnes, G.; Bureau, P.; Berlin, V. Antifungal activity of a Candida albicans GGTase I inhibitor-alanine conjugate. Inhibition of Rho1p prenylation in C. albicans. Bioorg. Med. Chem. Lett. 2003, 13, 1935-1937.